Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Fineline Cube Jul 21, 2026
Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Fineline Cube Jul 21, 2026
Company Deals

Samsung Biologics Bids $1.8 Billion for PolyPeptide Group to Enter High-Growth Peptide Therapeutics Market

Fineline Cube Jul 21, 2026
Company Deals

Akeso Biopharma Launches Greater Bay Area Charitable Program to Provide Free Ivonescimab to Hong Kong Lung Cancer Patients

Fineline Cube Jul 21, 2026
Company Deals

Hisun Pharmaceutical Secures Exclusive Rights to TISA-818 – Novel Multi-Target Immunomodulator for ARDS and Pulmonary Fibrosis

Fineline Cube Jul 21, 2026
Policy / Regulatory

China Launches 12th Batch of National Drug Procurement with Vonoprazan and Vitamin B6 Drawing Record Competition

Fineline Cube Jul 21, 2026
Company Drug

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Fineline Cube Jul 21, 2026
Company Drug

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Fineline Cube Jul 21, 2026
Company Deals

Shandong Jincheng Pharma Subsidiary Jincheng Taier to Sell Proxyl Vaginal Capsule Tech & MAH Rights to Shanghai Hemony for RMB 50 M

Fineline Cube Nov 6, 2025

Shandong Jincheng Pharmaceutical Group Co., Ltd. (SHE: 300233) disclosed that its wholly‑owned subsidiary Jincheng Taier...

Company Drug

Sinotau Receives FDA NDA Approval for MK‑6240 Tau PET Imaging Agent

Fineline Cube Nov 6, 2025

Beijing Sinotau International Pharmaceutical Technology Co., Ltd. announced today that the New Drug Application (NDA) for...

Company Deals

Baheal Pharma Locks CSL Behring Albumin Rights to Boost China’s Blood Product Supply

Fineline Cube Nov 6, 2025

Baheal Pharma Group (SHE: 301015), a prominent Chinese therapeutic manufacturer, announced an enhanced cooperation agreement...

Company Deals

Prelude Therapeutics Revamps Pipeline: Incyte Option on JAK2V617F, KAT6A Degrader Takes Center Stage, SMARCA2 Paused

Fineline Cube Nov 5, 2025

Prelude Therapeutics (NASDAQ: PRLD) unveiled a suite of strategic shifts: it signed an option deal...

Company Drug

UCB Wins FDA Approval for KYGEVVI in Rare Mitochondrial Disease TK2d

Fineline Cube Nov 5, 2025

UCB (EBR: UCB) announced that KYGEVVI received FDA approval for the treatment of adult and...

Company Drug

Dizal Highlights Breakthrough Findings for golidocitinib and birelentinib at ASH 2025

Fineline Cube Nov 5, 2025

Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced that multiple research updates for its two core...

Company Drug

Jiangsu Vcare’s VC004 Joins NMPA’s SPARK Oncology Program

Fineline Cube Nov 5, 2025

The Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) has officially...

Company

Pfizer’s Q3 2025 Results: COVID‑19 Sales Slide While Eliquis Soars

Fineline Cube Nov 5, 2025

US pharmaceutical heavyweight Pfizer Inc. (NYSE: PFE) posted Q3 2025 revenues of $16.7 B – a...

Company Drug

Jiangsu Hengrui Secures Priority Review for HRS‑5965 in China’s Rare‑Disease Portfolio

Fineline Cube Nov 5, 2025

Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration (NMPA)...

Company Drug

Pluvicto Radioligand Therapy Receives Dual NMPA Approvals in China

Fineline Cube Nov 5, 2025

Novartis (NYSE: NVS) has announced that its Lutetium‑177‑labelled therapy Pluvicto (lutetium ¹⁷⁷Lu‑vipivotide tetraxetan) now holds...

Company Drug

Sichuan Biokin Secures Breakthrough Therapy Designation for HER2‑Targeted ADC T‑Bren

Fineline Cube Nov 5, 2025

China’s Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that its proprietary antibody‑drug conjugate (ADC)...

Company Drug

Shenzhen Kangtai Biological Products Launches Phase I Trial for Infant Influenza Vaccine

Fineline Cube Nov 5, 2025

China‑based Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) has entered the clinical stage with...

Company Deals

4D Molecular Transfers Asia‑Pacific Gene‑Therapy Rights to Otsuka for $85 M Cash

Fineline Cube Nov 5, 2025

4D Molecular Therapeutics (4DMT) sold the Asia‑Pacific rights to its eye‑gene therapy 4D‑150 to Otsuka...

Company

Novo Nordisk Reports 15 % YoY Sales Growth, Cuts Full‑Year Guidance

Fineline Cube Nov 5, 2025

Denmark‑based biopharma Novo Nordisk A/S (NYSE: NVO) disclosed Q1‑Q3 2025 financials that show a 15 %...

Policy / Regulatory

China CDE Opens Public Comment on 100th Batch of Reference Standards for Chemical Generic Drugs

Fineline Cube Nov 5, 2025

The China Center for Drug Evaluation (CDE) has released a draft list of the 100th...

Company Deals Drug

MSD Secures Full Global Rights to MK‑8690 After $150 Million Settlement with Falk Pharma

Fineline Cube Nov 5, 2025

Merck Sharp & Dohme Inc. (MSD, NYSE: MRK), through its 2023 acquisition of Prometheus BioSciences,...

Policy / Regulatory

China’s National Health Commission Launches “Silver‑Haired” Healthcare & Elderly‑Care Initiative

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) has issued a formal notice to roll out the Silver‑Haired...

Policy / Regulatory

China’s National Health Commission Issues “AI + Healthcare” Implementation Opinions – Roadmap for 24 Standardized Applications

Fineline Cube Nov 5, 2025

The National Health Commission (NHC) today released the Implementation Opinions on Promoting and Standardizing the...

Company Drug

Zhejiang Acea Pharma Secures Conditional NMPA Approval for Olgotrelvir Sodium Capsules – First Dual‑Target COVID‑19 Oral Antiviral in China

Fineline Cube Nov 5, 2025

Zhejiang Acea Pharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has granted...

Company Drug

Daiichi Sankyo’s Enhertu Wins CDE Acceptance for First‑Line HER2‑Positive Breast‑Cancer Indication in China

Fineline Cube Nov 5, 2025

Daiichi Sankyo Co., Ltd. (TYO: 4568) announced that China’s Center for Drug Evaluation (CDE) of...

Posts pagination

1 … 115 116 117 … 697

Recent updates

  • Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market
  • GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood
  • Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention
  • Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics
  • Jacobio Pharmaceuticals’ JAB-8263 BET Inhibitor Proposed for NMPA’s Rare Disease “Caring Program” for Myelofibrosis Treatment
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Grand Pharma Partners with Siemens Healthineers to Commercialize AcuNav Lumos 4D ICE Catheter in China’s Structural Heart Market

Company Drug

GSK Submits Bexsero Label Update to EMA for Single-Dose Booster in Adolescents and Adults Previously Vaccinated in Childhood

Company Drug

Beijing Wantai’s RSV Vaccine Receives NMPA Clinical Trial Acceptance for Lower Respiratory Tract Disease Prevention

Company Deals Digital

Insilico Medicine Forms Quantum-AI Alliance with Byterna and DuneQ to Accelerate Next-Generation RNA and Peptide Therapeutics

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.